Water Vapor Ablation for Localized Intermediate Risk Prostate Cancer (NCT05683691)

🧪 Interventions in This Study

• Vanquish System (DEVICE)

Full eligibility criteria are available on the official NIH protocol. View the criteria ↗

📍 All Participating Trial Locations (25 Sites)

• Mayo Clinic- Phoenix — Phoenix, Arizona
• Memorial Care — Laguna Hills, California
• University of Southern California — Los Angeles, California
• Kasraeian Urology — Jacksonville, Florida
• University of Chicago — Chicago, Illinois
• Wichita Urology — Wichita, Kansas
• Chesapeake Urology — Baltimore, Maryland
• Johns Hopkins — Baltimore, Maryland
• Corewell Health / William Beaumont University Hospital — Royal Oak, Michigan
• Michigan Institute of Urology — Troy, Michigan
• University of Minnesota — Minneapolis, Minnesota
• Mayo Clinic- Rochester — Rochester, Minnesota
• Minnesota Urology — Woodbury, Minnesota
• NYU Langone Health — New York, New York
• Northwell Health- Lenox Hill Hospital — New York, New York
• University of Rochester — Rochester, New York
• Duke Cancer Institute — Durham, North Carolina
• The Urology Group — Cincinnati, Ohio
• MidLantic Urology — Bala-Cynwyd, Pennsylvania
• Carolina Urologic Research Center — Myrtle Beach, South Carolina
• Urology Austin — Austin, Texas
• Houston Methodist Hospital and Research Institute — Houston, Texas
• The Urology Place — San Antonio, Texas
• Urology of Virginia, PLLC — Virginia Beach, Virginia
• Medical College of Wisconsin — Milwaukee, Wisconsin

📞 Contact the Study Coordinator

Phone: (800) 664-4580

Coordinator details come directly from the registered NIH protocol. Confirm the study is still recruiting before traveling.

💰 Cost, Insurance & Patient Rights

• 100% Free Items: The investigational treatment and protocol-required procedures are supplied at zero cost by the sponsor.
• Routine Patient Care: Under federal law (ACA § 2709) and many state statutes, routine care costs are covered during participation.
• Voluntary Participation: You may withdraw at any time without affecting your standard medical care.

More studies in Prostate Cancer

• A Study of Apalutamide (JNJ-56021927, ARN-509) Plus Androgen Deprivation Therapy (ADT) Versus ADT in Participants With mHSPC — Homewood, Alabama
• A Study in Which Non-metastatic Castration-resistant Prostate Cancer (nmCRPC) Patients for Whom a Decision to Treat With Darolutamide Has Been Made Before Enrollment Are Observed and Certain Outcomes Are Described — Homewood, Alabama
• Stereotactic Ablative Radiation Therapy for Prostate Cancer — Charleston, South Carolina
• A Study of Stereotactic Body Radiation Therapy (SBRT) Without Androgen Deprivation Therapy (ADT) in People With Unfavorable Intermediate-Risk Prostate Cancer — Basking Ridge, New Jersey
• A Study of Abiraterone Acetate Plus Prednisone With or Without Abemaciclib (LY2835219) in Participants With Prostate Cancer — Phoenix, Arizona
• Neoadjuvant Enoblituzumab (MGA271) in Men With Localized Intermediate and High-Risk Prostate Cancer — Baltimore, Maryland

Explore by condition: All Prostate Cancer clinical trials

💡 How to Participate

1. Check the checklist above to see if you may qualify.
2. Contact the study coordinator using the phone/email above.
3. Ask about the visit schedule, what is covered at no cost, and any travel support.
4. Confirm with your own doctor before making a decision.